Agricultural Revolution with Mustard Power: How MustGrow Is Capitalizing on the Crisis
Canadian-based MustGrow Biologics Corp. operates in an agricultural market that is under constant geopolitical stress and is simultaneously undergoing profound structural change. Regardless of short-term geopolitical developments, the structural shift toward more resilient and less fossil-dependent agricultural inputs remains intact. Farmers are increasingly frustrated by volatile input costs and are seeking to reduce long-term reliance on conventional fertilizers. MustGrow addresses this “weak link” with mustard-derived solutions that, in addition to outstanding fertilizing properties, also support microbial activity and enhance yield stability.
Significant momentum was already evident in the company’s operations in 2025. Revenue jumped to CAD 8.3 million after just CAD 0.4 million in the previous year, impressively underscoring the beginning of commercialization (majority of sales were from the company’s sales and distribution division, NexusBioAg, which was shuttered in April 2026). At the same time, rising expenses of CAD 7.7 million and a net loss of CAD 7.3 million reflect the typical investment phase of a scaling model. Particularly noteworthy is the growth of the flagship product TerraSante, whose US revenue increased by 377% to approximately CAD 0.6 million. At times, demand exceeded supply, shifting additional revenue into the future. With a gross margin of about 20%, profitability still has room for improvement but is expected to increase significantly as production scales up and supply chains become more efficient. The decision to discontinue low-margin sales activities in Canada and direct capital specifically toward US expansion serves to sharpen the business model and should enable the company to reach operational breakeven more quickly.
At the same time, market development is progressing. With its license in Georgia, MustGrow is gaining access to one of the most profitable agricultural states in the US, which generates over USD 700 million in revenue from peanuts alone. These regulatory advances complement existing certifications in key growing regions such as California and Florida and create a solid foundation for recurring revenue. Strategic partnerships, including one with Bayer AG, serve as a gateway to international markets and lend the technology additional credibility.
CEO and President Corey Giasson will present MustGrow’s 2026/27 strategy at the 19th International Investment Forum on May 20, 2026.Click here to register.
From a macroeconomic perspective, MustGrow is part of a market for biological agricultural solutions projected to reach approximately USD 35 billion by 2030, with annual growth rates exceeding 13%. Especially against the backdrop of fragile supply chains and potential shortages of conventional fertilizers, the business model acts as insurance against external shocks. Even if the situation in the Strait of Hormuz eases, the realization remains that resilience in agriculture is increasingly defined by input independence. With approximately 63 million shares outstanding, the CAD 36 million valuation remains moderate relative to the addressed market size. The CAD 2 million capital raise in January is intended to ramp up production and better meet demand. For risk-aware investors, the MustGrow stock offers an exciting setup for a sustainable future in food production. The current consolidation in the range of CAD 0.52 to 0.64 is likely to conclude soon. Highly interesting!
K+S – Easing tensions in the Gulf triggers a sell-off
The easing of tensions in the Gulf led to a noticeable price decline of just under 10% for the MDAX-listed K+S. This significantly puts the March premium back into perspective. Currently, investors appear to be focusing more on the fundamentals again. A showdown for the first quarter of 2026 is set for May 11. Analysts’ consensus estimate is for a net profit of EUR 0.57 per share. The annual general meeting will take place the following day. If the majority of analysts’ expectations are met, K+S could generate an EBIT of over EUR 250 million in 2026. Some extraordinary income may also be added due to higher prices resulting from the Middle East conflict. The majority of experts on the LSEG Refinitiv platform expect a share price of EUR 15.32 over the next 12 months. That would be almost exactly the current price level. Perhaps CEO Christian Meyer has some surprises in store.
Novo Nordisk and Evotec: Current outlooks mark an important turning point
The first quarter appears to be a turning point for some companies in the life sciences sector. Although Novo Nordisk has felt under constant pressure for the past 12 months and missed every target in 2025, sentiment now seems to be improving dramatically. GLP-1-based therapies for diabetes and obesity continue to see exponential demand, as CEO Maziar Mike Doustdar recently stated in the press. Pricing power in these indications, combined with high production utilization and continuous capacity expansions, is driving above-average revenue and profit growth. Added to this is a strong pipeline that broadens the ecosystem around metabolic diseases and raises the barriers to entry for competitors. The Scandinavian company is encouraged by the surprisingly strong start to the year. The popular retail stock gained over 20% in just one week. From a technical perspective, the share price now only needs to top the EUR 42 mark, after which the outlook is likely to improve further.
Things are also heating up at Evotec. The current strength in the stock price primarily reflects the increasing monetization of the successful platform model, in which scalable drug discovery is converted into recurring milestone and licensing payments through partnerships. Although the first quarter was seasonally weak, the raised annual forecast was maintained. Investment bank RBC has once again confirmed its “Outperform” rating and set a target price of EUR 10. Some argue that takeover speculation is still on the table. After all, the Hamburg-based drug researchers are valued at only 1.3 times revenue based on 2026. Operationally, the restructuring finally seems to be paying off. Those with a long-term perspective are buying in!
The life sciences sector is still moving cautiously on the trading floor, but sentiment is clearly turning positive. Stocks like Novo Nordisk and Evotec are poised to make their usual mark again in 2026. CropScience pioneer MustGrow Biologics remains a major eye-catcher: With its patented mustard-derived technology, the company is moving out of the niche and into the spotlight—bringing real valuation jumps within reach. K+S benefited from a brief rally, but the euphoria seems to be fading again.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.